Products
& platforms
Adocia mission is to develop innovative formulations of approved peptides and novel cell therapy approaches for the treatment of diabetes and obesity.
- Home
- >
- Products and platforms
- >
- Pipeline
Pipeline
Over the years, Adocia has built a diversified pipeline of specialty products for the treatment of diabetes and obesity.
The products development stage ranges from preclinical proof of concept to Phase 3 clinical trials.
BioChaperone® GLP-1 Amylin
Product description: BioChaperone® makes it possible to stabilize and co-formulate amylin and GLP-1 in a single product, and enables the use of multi-use pens.
Platform: BioChaperone®
BioChaperone®
Lispro
Phase 3 in USA / Europe ready to start upon partnership signature
Partnering: Licensed to Tonghua Dongbao for China and other Asian territories. Available for other territories.
Product description: BioChaperone® Lispro (BC Lispro) is a novel ultra-rapid prandial insulin formulation containing insulin lispro and Adocia proprietary technology platform BioChaperone®. The BioChaperone® excipient ensures a faster absorption of insulin post injection and enables a more effective management of blood glucose levels.
Platform: BioChaperone®
AdoShell®
Islets
Demonstrated in vivo maturation and efficacy with stem cell-derived islets
Product description: AdoShell® Islets is a hydrogel-based implant containing islets of Langerhans or stem cell-derived islets for cell therapy against type 1 diabetes.
It improves significantly the current transplantation protocols by removing the immunosuppressive treatment and making the implanted islets retrievable.
Platform: AdoShell®
AdOral®
Sema
Product description: AdOral® Sema is an orally administered glucagon-like peptide 1 (GLP1) receptor agonist: semaglutide. Adocia has applied its AdOral® technology to switch the active molecule from an injectable to an oral form.
Platform: AdOral®
AdoXLongTM Sema
Product description: AdoXLongTM Sema is a long-acting formulation of semaglutide that allows a switch from weekly injections to monthly injections. Positive preliminary in vitro and in vivo results have been obtained.
Platform: AdoXLongTM
M1Pram
Partnering: Sanofi
Product description: M1Pram is a ready-to-use co-formulation of pramlintide (an amylin analog) and M1 (a mealtime insulin analog).
Adocia has developed M1Pram to enable patients affected by both diabetes and overweight or obesity to address weight management and glycemic control as co-primary targets of care.